The U.S. Food and Drug Administration has accepted Pfizer's Biologics License Application for inotuzumab ozogamicin. Read More »

Pfizer Inc. recently released top-line results for ORAL Strategy, a Phase 3B/4 study of XELJANZ (tofacitinib citrate) 5mg twice daily in the treatment of moderate to severe rheumatoid arthritis. Read More »

Genentech, a member of the Roche Group, recently announced its Phase II IMmotion150 study delivered promising results. Read More »

The biggest pharmaceutical event series in the world, the CPhl, will take place May 16-18 in Philadelphia and feature over 55 speakers. Read More »

BioPharmX Corp., a leading pharmaceutical company developing and promoting health products for the dermatology and women’s market, revealed it has completed the “last subject visit in its Phase 2b trial,” as of March. Read More »

Shire PLC has published results from its Phase 1b lanadelumab study in the New England Journal of Medicine. Read More »

ArQule Inc. and Daiichi Sankyo's METIV-HCC Phase 3 study of tivantinib in hepatocellular carcinoma failed to meet its primary endpoint of improving overall survival. Read More »

Genentech's Phase II Mmotion150 study for Tecentriq compared Tecentriq plus Avastin and Tecentriq monotherapy to sunitinib alone reinforced the potential of the combination drug for the treatment of patients with previously untreated, locally advanced or metastatic renal cell carcinoma. Read More »

GlaxoSmithKline (GSK) and Innoviva Inc. recently released positive results for a study evaluating Relvar Ellipta in treating asthma. Read More »

AbbVie has announced the successful results of an EXPEDITION-1 Phase III study that evaluated 12 weeks of treatment with glecaprevir/pibrentasvir (G/P). Read More »

New data on OCREVUS presented at American Academy of Neurology (AAN) annual meeting in Boston. Read More »

Shire's Vyvanse (lisdexamfetamine dimesylate) CII is now available in a chewable tablet formulation, making it the only Attention-Deficit/Hyperactivity Disorder and Binge Eating Disorder treatment available in five administration options. Read More »

Amgen recently announced that a planned overall survival (OS) interim analysis of the Phase 3 head-to-head Endeavor trial delivered positive results. Read More »

Genentech, along with the Breast International Group, Breast European Adjuvant Study Team and Frontier Science Foundation, recently reported positive results from the Phase III Aphinity study for combining Perjeta, Herceptin and chemotherapy in treating certain breast cancer patients. Read More »

Biogen will present data on its treatments and investigational treatments for people with multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease at the upcoming American Academy of Neurology annual meeting in Boston. Read More »

Amgen recently unveiled new data from the Kyprolis and Xgeva clinical development programs at the 16th International Myeloma Workshop in New Delhi. Read More »

Amgen's results from its Phase 3 Tower study evaluating Blincyto’s efficacy have been published in the New England Journal of Medicine. Read More »

Merck & Co. Inc. recently released the results of its Phase 3 clinical study of letermovir, a drug used to prevent clinically significant cytomegalovirus infection in CMV-seropositive adult recipients of an allogeneic hematopoietic stem cell transplant, also known as bone marrow transplant. Read More »

Sandoz, a division of Novartis, has selected six finalists for the Sandoz HACk Healthcare Access Challenge. Read More »

McKesson, the platinum sponsor of CBI’s Formulary, Co-Pay and Access Summit is presenting a new approach to patient-centric behavioral coaching with the overall goal of improving adherence despite affordability and other barriers. Read More »